In 2025, the U.S. medical aesthetics industry has faced a dual-threat environment of broad baseline tariffs and aggressive, targeted reciprocal penalties. Because the industry relies on global supply chains for everything from active ingredients to specialized glass syringes, these policies have led to the most significant price volatility in the sector’s history.
The following is a summary of the real and threatened effects as of late 2025.
Realized Effects (In Force)
As of the second half of 2025, several tariffs have moved from proposal to active enforcement, directly impacting clinic overhead.
• The 10% Universal Baseline Tariff: Implemented on April 5, 2025, this blanket duty applies to nearly all imported goods. This has created an immediate price floor increase for European fillers (like Restylane) and Asian energy devices.
• Targeted Consumables Surge: Consumables from China have been hit hardest to encourage domestic reshoring. Practitioners report a 20–25% increase in the cost of a standard injection setup (gauze, saline, and needles).
o Syringes and Needles: Increased to a 100% tariff in 2025.
o Nitrile Gloves: Rose to 50% in 2025 (scheduled for 100% in 2026).
• The Device Penalty: While some pharmaceuticals were initially spared, dermal fillers are classified as medical devices by the FDA. This has subjected them to the baseline 10% tariff plus any country-specific duties (such as 25% for Mexican/Canadian imports under revised USMCA rules). In contrast, neuromodulators (like Botox) were initially classified as pharmaceuticals, which shielded them from the first wave of broad tariffs, though this protection weakened by Q4.
• Front-Running Costs: In early 2025, panic buying caused a temporary 7% spike in imports as clinics sought to stock up before April deadlines, followed by a sharp drop in orders and a subsequent 10–12% rise in wholesale prices.
• Shrinking Margins: Some large medical spa chains, which operate on high volume and thin margins, have been forced to implement “Supply Surcharge” fees (typically $15–$50 per visit) rather than raising the per-unit price of products like tox to keep their marketing transparent.
Threatened Effects and The October Pivot
The industry experienced significant instability in late 2025 due to reciprocal tariff threats used as a negotiation lever.
• The 100% Branded Pharma Threat: In late September 2025, the administration threatened a 100% tariff on branded pharmaceutical imports (targeting Botox from Ireland and Jeuveau from South Korea). See below “Reshoring Movement” section for more specifics on this.
• The Negotiation Pause: As of October 1, 2025, this 100% tariff has been paused for many nations (including the EU) to allow for “Most Favored Nation” (MFN) price negotiations. The threat remains active as a cudgel to force manufacturers to lower U.S. prices or move manufacturing to American soil.
• Semiconductor Tariffs: A threatened 100% tariff on semiconductors (announced August 2025) has stalled the purchase of new high-end lasers and RF devices. Manufacturers are warning of potential 30% price hikes on new equipment if these tariffs move forward.
Impact Summary by Category
Neurotoxins
Origin: Ireland, UK, Germany
2025 Real/Threatened Impact: Currently 10% baseline; 100% threat “on pause” pending negotiations.
Dermal Fillers
Origin: France, Sweden, S. Korea
2025 Real Impact: 10% – 25% real increase; classified as devices.
Energy Devices
Origin: Israel, China
2025 Real/Threatened Increase: 25% – 145% real increase on parts/components; high capital cost.
Medical Consumables
Origin: China
2025 Real Increase: 100% Real increase on needles/syringes; driving up daily overhead.
Market and Consumer Consequences
• The Supply Surcharge: Rather than constantly re-printing menus, many med spas have implemented a flat “Tariff/Supply Surcharge” (typically $15–$30) per appointment to cover the rising cost of gloves and needles.
• Innovation Slowdown: Industry analysts note that manufacturers are cutting R&D budgets to offset tariff expenses, potentially delaying the U.S. launch of next-generation biostimulators.
• Counterfeit Incentive: The high cost of legal, tariffed goods has inadvertently boosted the underground market, with some providers turning to non-tariffed gray market imports to stay price-competitive.
Reshoring Movement to Avoid Tariffs
In 2025, the threat of a 100% reciprocal tariff on imported pharmaceuticals has triggered a massive “reshoring” movement. To qualify for exemptions, many companies are scrambling to meet the administration’s “Is Building” definition, which requires that they have officially broken ground or have facilities under construction in the U.S.
The following manufacturers have made official announcements regarding new or expanded U.S. manufacturing facilities to bypass these 2025 tariffs:
Galderma (Restylane, Dysport, Relfydess)
In one of the most significant pivots of 2025, the Swiss-based giant committed to a $650 million U.S. manufacturing investment through 2030.
• The Move: Galderma is shifting final assembly and packaging of its blockbuster products to U.S.-based contractors.
• Key Asset: A major focus is the technology transfer for Relfydess (RelabotulinumtoxinA) to the U.S. to ensure its 2025/2026 launch is not crippled by the 100% tariff.
• Location: Expansion of operations in Florida and the Dallas-Fort Worth area.
AbbVie/Allergan Aesthetics (Botox, Juvéderm)
While AbbVie already has a strong U.S. presence, it announced a specific $195 million investment in August 2025 to further insulate its portfolio from trade volatility.
• The Move: Expansion of its North Chicago, Illinois, plant to increase domestic production of Active Pharmaceutical Ingredients (API).
• Timeline: Construction began in Fall 2025, with the site expected to be fully operational by 2027. This breaking ground status is intended to shield their upcoming product pipeline from the 100% branded drug tariff.
Crown Laboratories/Revance Therapeutics (Daxxify, SkinPen)
Following Crown Laboratories’ acquisition of Revance in early 2025, the merged entity has leaned heavily into its “Made in America” status.
• The Advantage: Unlike its competitors, Daxxify is manufactured in California. Crown is leveraging this to avoid the 100% pharmaceutical tariff entirely, positioning Daxxify as the tariff-proof alternative to other tox options.
• Expansion: Crown (ranked on the 2025 Inc. 5000) has expanded its Johnson City, Tennessee, facilities to accommodate the increased demand for its U.S.-manufactured SkinPen device.
Evolus (Jeuveau, Evolysse)
As a smaller company, Evolus took a financial approach to the 2025 tariffs rather than building a factory from scratch.
• Inventory Hoarding: In its Q3 2025 financial report, Evolus disclosed that it used a significant portion of its cash reserves ($43.5M) for “proactive inventory purchases” ahead of the October 1 tariff deadline.
• Strategic Sourcing: While its products are manufactured in South Korea (toxin) and Europe (fillers), Evolus is using these stockpiles to maintain price stability while negotiating potential MFN pricing status with the U.S. government.
Next Up: Part VI in Christensen Consulting’s 2025 Medical Aesthetic Year in Review, All Things K-Pop.
Read past installments of this report:
Part I: New Indications, Approvals, and Entrants Into the Market
Part II: A Focus on Pumping Up Filler Futures
Part III: The Incredible Journey of GLP-1s
Part IV: The Dangerous Impact of Problem Practitioners
Leave a Reply